HAIC of OXA

Phase 3Small molecule

SSun Yat-sen University

HAIC of OXA is one of 62 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholangiocarcinomaRecruiting

Hepatocellular CarcinomaNot yet recruiting

Intrahepatic CholangiocarcinomaPhase 3

Recruiting

Hepatocellular CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

251 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

HAIC of OXA

SSun Yat-sen University

Phase 3

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Doptelet

AAkarx

Preclinical

1 8

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 9

Vermox

WWim Janssens

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Hepatocellular Carcinoma

NCT07012798

Clinical

Trials by Indication[1]

Sorafenib2 trials

HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

Completed·SSun Yat-sen University·Phase 3·NCT02856126·214 enrolled

Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

Unknown status·SSun Yat-sen University·Phase 2·NCT03812770·150 enrolled

Unresectable1 trial

Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial

Unknown status·SSun Yat-sen University·Phase 3·NCT04687163·400 enrolled

Refractory1 trial

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Withdrawn·SSun Yat-sen University·Phase 2·NCT03722498

Hepatocellular Carcinoma1 trial

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07012798·30 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Recruiting·—·Phase 4·NCT05124002·66 enrolled

1 more indication

Advanced1 trial

HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

Unknown status·SSun Yat-sen University·Phase 3·NCT03468231·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for HAIC of OXA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HAIC of OXA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HAIC of OXA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

HAIC of OXA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Sorafenib2 trials

Unresectable1 trial

Refractory1 trial

Hepatocellular Carcinoma1 trial

Intrahepatic Cholangiocarcinoma1 trial

Advanced1 trial

References

Drug Info

Quick Facts

Related News